313 related articles for article (PubMed ID: 18752081)
21. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
22. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
[TBL] [Abstract][Full Text] [Related]
23. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Shimada YJ
Acta Oncol; 2013 May; 52(4):691-702. PubMed ID: 23282114
[TBL] [Abstract][Full Text] [Related]
24. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
25. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
28. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Kappers MH; van Esch JH; Sluiter W; Sleijfer S; Danser AH; van den Meiracker AH
Hypertension; 2010 Oct; 56(4):675-81. PubMed ID: 20733093
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib in solid tumors.
Gan HK; Seruga B; Knox JJ
Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
Noda S; Otsuji T; Baba M; Yoshida T; Kageyama S; Okamoto K; Okada Y; Kawauchi A; Onishi H; Hira D; Morita SY; Terada T
Clin Genitourin Cancer; 2015 Aug; 13(4):350-358. PubMed ID: 25701374
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
33. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
Kalra S; Rini BI; Jonasch E
Ann Oncol; 2015 Jul; 26(7):1300-4. PubMed ID: 25628443
[TBL] [Abstract][Full Text] [Related]
34. Management of antiangiogenic therapy-induced hypertension.
de Jesus-Gonzalez N; Robinson E; Moslehi J; Humphreys BD
Hypertension; 2012 Sep; 60(3):607-15. PubMed ID: 22851729
[No Abstract] [Full Text] [Related]
35. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Kollmannsberger C; Bjarnason G; Burnett P; Creel P; Davis M; Dawson N; Feldman D; George S; Hershman J; Lechner T; Potter A; Raymond E; Treister N; Wood L; Wu S; Bukowski R
Oncologist; 2011; 16(5):543-53. PubMed ID: 21490127
[TBL] [Abstract][Full Text] [Related]
36. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Pilotte AP
Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
[TBL] [Abstract][Full Text] [Related]
37. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
38. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
40. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
Gallucci G; Tartarone A; Tocchetti CG; Bochicchio AM; Coccaro M; Capobianco A; Maurea N; Improta G; Zupa A; Aieta M
Future Oncol; 2013 Jan; 9(1):127-33. PubMed ID: 23252570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]